MannKind Corporation (MNKD) stock surged +1.77%, trading at $7.22 on NASDAQ, up from the previous close of $7.09. The stock opened at $7.02, fluctuating between $7.01 and $7.23 in the recent session.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Employees | 411 |
Beta | 1.313 |
Sales or Revenue | $198.96M |
5Y Sales Change% | 2.855% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
MannKind Corporation (NASDAQ: MNKD) stock price is $7.22 in the last trading session. During the trading session, MNKD stock reached the peak price of $7.23 while $7.01 was the lowest point it dropped to. The percentage change in MNKD stock occurred in the recent session was 1.77% while the dollar amount for the price change in MNKD stock was $0.13.
The NASDAQ listed MNKD is part of Biotechnology industry that operates in the broader Healthcare sector. MannKind Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Rosabel Realica Alinaya
Vice President of Investor Relations & Treasury
Mr. John F. Bedard
Senior Vice President of Worldwide Regulatory Affairs
Mr. James Patrick McCauley Jr., J.D., M.B.A.
Chief Commercial Officer
Dr. Stuart A. Tross Ph.D.
Executive Vice President and Chief People & Workplace Officer
Mr. Joseph Kocinsky M.B.A., M.S.
Chief Technology Officer
Dr. Michael E. Castagna Pharm.D.
Chief Executive Officer & Director
Mr. Steven B. Binder
Chief Financial Officer
Dr. David B. Thomson
Executive Vice President, Gen. Counsel & Sec.
Mr. Sanjay Singh M.B.A.
Executive Vice President of Technical Operations
Ms. Lauren M. Sabella
Executive Vice President & Chief Operating Officer
Mr. Thomas Hofmann M.D., Ph.D.
Senior Vice President & Chief Scientific Officer
MNKD's closing price is 123.66% higher than its 52-week low of $3.17 where as its distance from 52-week high of $7.33 is -3.21%.
Number of MNKD employees currently stands at 411.
Official Website of MNKD is: https://www.mannkindcorp.com
MNKD could be contacted at phone 818 661 5000 and can also be accessed through its website. MNKD operates from 30930 Russell Ranch Road, Westlake Village, CA 91362, United States.
MNKD stock volume for the day was 522.37K shares. The average number of MNKD shares traded daily for last 3 months was 2.32M.
The market value of MNKD currently stands at $1.98B with its latest stock price at $7.22 and 275M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com